PRKAA2 and metabolic dysfunction-associated steatotic liver disease: Notably, NAFLD [containing interleukin-6 (IL-6), BH3 interacting domain death agonist (BID), and protein kinase AMP-activated catalytic subunit alpha 2 (PRKAA2) genes] was the major biological pathway involved and was consistently identified by WebGestalt, DAVID, and Metascape.